PPARGC1A and metabolic dysfunction-associated steatotic liver disease: This synergistic FOXO-mediated transcriptional Atg14- and lpl-up-regulation (Fig. 5A) along with the observed AMPK-FOXO-PGC1α-mediated acox1-up-regulation (Fig. 5A) and pACC2-attenuation (through S79-phosphorylation; Fig. 5A,B) in CHIP−/−-livers would synergistically enhance both lipid-breakdown and mitochondrial FA-uptake and β-oxidation, thereby promoting the anti-steatogenic effects of activated adiponectin-AMPK-FOXO-signaling, and retarding NAFLD/NASH-progression.